Renalytix PLC at H C Wainwright Global Investment Conference Transcript

Sep 12, 2022 / 11:00AM GMT
Lee Chan - H.C. Wainwright & Co., LLC - Analyst

Thank you for joining the H.C. Wainwright 24th Annual Global Investment Conference. My name is Lee Chan, and I'm a healthcare analyst at H.C. Wainwright. Today, we have Mr. James McCullough, CEO of Renalytix join us for fireside chat. Welcome, James.

James McCullough - Renalytix PLC - CEO

Good afternoon. I'm delighted to be here.

Questions and Answers:

Lee Chan - H.C. Wainwright & Co., LLC - Analyst

So Renalytix markets the KidneyIntelX test for prognosis of kidney [accounts]. Could you tell us what the test measures and how physicians can use that [test result]?

James McCullough - Renalytix PLC - CEO

Yeah. So KidneyIntelX is really a program where -- which is based on an in vitro diagnostic. So we take a blood drop. And we measure three circulating proteins, which have a long history in the literature of understanding kidney disease progression. And to that, we add a whole sequence of features from a patient's
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot